{"id":68235,"date":"2026-06-15T22:22:36","date_gmt":"2026-06-15T14:22:36","guid":{"rendered":"https:\/\/flcube.com\/?p=68235"},"modified":"2026-06-15T22:22:37","modified_gmt":"2026-06-15T14:22:37","slug":"lannacheng-biotechnology-files-hkex-prospectus-with-13-candidate-radiopharmaceutical-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68235","title":{"rendered":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Yantai Lannacheng Biotechnology Co., Ltd.<\/strong> announced it has filed its <strong>prospectus for listing on the Hong Kong Stock Exchange<\/strong>, unveiling a comprehensive pipeline of <strong>13 radiopharmaceutical candidates<\/strong> for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on <strong>radiopharmaceuticals<\/strong>, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.<\/p>\n\n\n\n<h2 id=\"h-company-profile-amp-strategic-focus\" class=\"wp-block-heading\">Company Profile &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Founded<\/strong><\/td><td>2021<\/td><\/tr><tr><td><strong>Stage<\/strong><\/td><td>Clinical-stage biotechnology company<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Radiopharmaceuticals for oncology<\/td><\/tr><tr><td><strong>Pipeline Size<\/strong><\/td><td>13 drug candidates<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Global development with China foundation<\/td><\/tr><tr><td><strong>Listing Target<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pipeline-composition\" class=\"wp-block-heading\">Pipeline Composition<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic Radiopharmaceuticals:<\/strong> 7 candidates<\/li>\n\n\n\n<li><strong>Therapeutic Radiopharmaceuticals:<\/strong> 6 candidates<\/li>\n\n\n\n<li><strong>Core Products:<\/strong> 4 lead candidates (detailed below)<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Registration-stage to preclinical candidates<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-core-product-portfolio\" class=\"wp-block-heading\">Core Product Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Type<\/th><th>Target<\/th><th>Indication<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>\u00b9\u2078F-LNC1001<\/strong><\/td><td>Diagnostic<\/td><td>PSMA<\/td><td>PSMA-positive prostate cancer PET imaging<\/td><td>Registration-stage<\/td><\/tr><tr><td><strong>\u00b9\u2078F-LNC1005<\/strong><\/td><td>Diagnostic<\/td><td>FAP<\/td><td>Gastric cancer PET imaging<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>\u00b9\u2077\u2077Lu-LNC1011<\/strong><\/td><td>Therapeutic<\/td><td>PSMA<\/td><td>PSMA-positive mCRPC treatment<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>\u00b9\u2078F-LNC1007<\/strong><\/td><td>Diagnostic<\/td><td>FAP\/\u03b1v\u03b23<\/td><td>Metastatic ccRCC PET imaging<\/td><td>Clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-analysis\" class=\"wp-block-heading\">Market Opportunity Analysis<\/h2>\n\n\n\n<h3 id=\"h-radiopharmaceutical-market-context\" class=\"wp-block-heading\">Radiopharmaceutical Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Growth:<\/strong> Radiopharmaceuticals market projected to exceed <strong>$12 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Theranostic Trend:<\/strong> Growing integration of diagnostic and therapeutic radiopharmaceuticals<\/li>\n\n\n\n<li><strong>China Opportunity:<\/strong> Expanding nuclear medicine infrastructure and regulatory support<\/li>\n\n\n\n<li><strong>Unmet Needs:<\/strong> Limited radiopharmaceutical options for gastric cancer and ccRCC imaging<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Potential:<\/strong> \u00b9\u2078F-LNC1005 for gastric cancer represents novel diagnostic approach<\/li>\n\n\n\n<li><strong>PSMA Leadership:<\/strong> Dual PSMA candidates (diagnostic + therapeutic) enable theranostic strategy<\/li>\n\n\n\n<li><strong>Technical Differentiation:<\/strong> FAP\/\u03b1v\u03b23 dual-targeting for ccRCC addresses complex tumor biology<\/li>\n\n\n\n<li><strong>Pipeline Breadth:<\/strong> 13-candidate portfolio demonstrates robust discovery capabilities<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-development-approach\" class=\"wp-block-heading\">Strategic Development Approach<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s strategy leverages <strong>complementary diagnostic and therapeutic pairs<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PSMA Platform:<\/strong> \u00b9\u2078F-LNC1001 (diagnostic) + \u00b9\u2077\u2077Lu-LNC1011 (therapeutic) for prostate cancer<\/li>\n\n\n\n<li><strong>FAP Targeting:<\/strong> Multiple FAP-targeted diagnostics for different solid tumors<\/li>\n\n\n\n<li><strong>Novel Targets:<\/strong> FAP\/\u03b1v\u03b23 dual-targeting addresses tumor microenvironment complexity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-commercial-implications\" class=\"wp-block-heading\">Financial &amp; Commercial Implications<\/h2>\n\n\n\n<h3 id=\"h-ipo-considerations\" class=\"wp-block-heading\">IPO Considerations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Raising:<\/strong> Proceeds to fund clinical development and manufacturing scale-up<\/li>\n\n\n\n<li><strong>Market Valuation:<\/strong> Radiopharmaceutical companies commanding premium valuations globally<\/li>\n\n\n\n<li><strong>Investor Appeal:<\/strong> Pure-play radiopharmaceutical exposure attractive to specialized biotech investors<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-strategy\" class=\"wp-block-heading\">Commercial Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Partnerships:<\/strong> Potential licensing deals with major pharmaceutical companies<\/li>\n\n\n\n<li><strong>Manufacturing Infrastructure:<\/strong> Investment in GMP-compliant radiopharmaceutical production<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Leveraging China&#8217;s growing nuclear medicine adoption while pursuing global markets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-pathway-amp-timeline\" class=\"wp-block-heading\">Regulatory Pathway &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u00b9\u2078F-LNC1001:<\/strong> Near-term NDA submission as registration-stage candidate<\/li>\n\n\n\n<li><strong>Other Candidates:<\/strong> Progressive clinical development across multiple indications<\/li>\n\n\n\n<li><strong>NMPA Engagement:<\/strong> Priority review potential for innovative radiopharmaceuticals<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Parallel development strategies for global regulatory submissions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-industry-context-amp-innovation\" class=\"wp-block-heading\">Industry Context &amp; Innovation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Lannacheng&#8217;s focus on <strong>tumor-specific targets<\/strong> (PSMA, FAP, \u03b1v\u03b23) reflects the latest advances in molecular imaging and targeted radiotherapy. The company&#8217;s emphasis on <strong>gastric cancer and ccRCC<\/strong> addresses significant unmet needs in radiopharmaceutical development, where most competitors focus primarily on prostate cancer and neuroendocrine tumors.<\/p>\n\n\n\n<h2 id=\"h-risk-considerations\" class=\"wp-block-heading\">Risk Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development Risk:<\/strong> Radiopharmaceutical trials require specialized imaging infrastructure<\/li>\n\n\n\n<li><strong>Manufacturing Complexity:<\/strong> Short half-lives require sophisticated logistics and distribution networks<\/li>\n\n\n\n<li><strong>Regulatory Uncertainty:<\/strong> Evolving regulatory frameworks for novel radiopharmaceuticals<\/li>\n\n\n\n<li><strong>Market Adoption:<\/strong> Physician education and infrastructure requirements for new imaging agents<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IPO plans, clinical development, and commercial expectations. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26061202230_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26061202230_c.\"><\/object><a id=\"wp-block-file--media-52116d12-70b9-4940-84bf-6e3a7c14c9cc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26061202230_c.pdf\">sehk26061202230_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26061202230_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-52116d12-70b9-4940-84bf-6e3a7c14c9cc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68238,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,72,3692],"class_list":["post-68235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-ipo","tag-lannacheng-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the Hong Kong Stock Exchange, unveiling a comprehensive pipeline of 13 radiopharmaceutical candidates for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on radiopharmaceuticals, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68235\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline\" \/>\n<meta property=\"og:description\" content=\"Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the Hong Kong Stock Exchange, unveiling a comprehensive pipeline of 13 radiopharmaceutical candidates for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on radiopharmaceuticals, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68235\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T14:22:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T14:22:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline\",\"datePublished\":\"2026-06-15T14:22:36+00:00\",\"dateModified\":\"2026-06-15T14:22:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235\"},\"wordCount\":517,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1510.webp\",\"keywords\":[\"Cancer\",\"IPO\",\"Lannacheng Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68235#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68235\",\"name\":\"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1510.webp\",\"datePublished\":\"2026-06-15T14:22:36+00:00\",\"dateModified\":\"2026-06-15T14:22:37+00:00\",\"description\":\"Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the Hong Kong Stock Exchange, unveiling a comprehensive pipeline of 13 radiopharmaceutical candidates for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on radiopharmaceuticals, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68235\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68235#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the Hong Kong Stock Exchange, unveiling a comprehensive pipeline of 13 radiopharmaceutical candidates for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on radiopharmaceuticals, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68235","og_locale":"en_US","og_type":"article","og_title":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline","og_description":"Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the Hong Kong Stock Exchange, unveiling a comprehensive pipeline of 13 radiopharmaceutical candidates for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on radiopharmaceuticals, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.","og_url":"https:\/\/flcube.com\/?p=68235","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T14:22:36+00:00","article_modified_time":"2026-06-15T14:22:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68235#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68235"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline","datePublished":"2026-06-15T14:22:36+00:00","dateModified":"2026-06-15T14:22:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68235"},"wordCount":517,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68235#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp","keywords":["Cancer","IPO","Lannacheng Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68235#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68235","url":"https:\/\/flcube.com\/?p=68235","name":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68235#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68235#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp","datePublished":"2026-06-15T14:22:36+00:00","dateModified":"2026-06-15T14:22:37+00:00","description":"Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the Hong Kong Stock Exchange, unveiling a comprehensive pipeline of 13 radiopharmaceutical candidates for oncological diagnosis and treatment. Founded in 2021, the clinical-stage biotechnology company focuses exclusively on radiopharmaceuticals, with four core products targeting prostate cancer, gastric cancer, and renal cell carcinoma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68235#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68235"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68235#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp","width":1080,"height":608,"caption":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68235#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68235"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68235\/revisions"}],"predecessor-version":[{"id":68239,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68235\/revisions\/68239"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68238"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}